Zobrazeno 1 - 10
of 15
pro vyhledávání: '"L B, Tyson"'
Publikováno v:
Cancer. 78(10)
Because of the predictability of significant emesis after its use, cisplatin serves as the standard emetic stimulus for trials of antiemetic drugs. To define better the incidence, severity, and pattern of emesis that follows cisplatin, facilitate the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::09d8a39dc5c551231c8c631d9ef25778
https://pubmed.ncbi.nlm.nih.gov/8918414
https://pubmed.ncbi.nlm.nih.gov/8918414
Autor:
K M, Pisters, L B, Tyson, W, Tong, M, Fleisher, V A, Miller, S C, Grant, D G, Pfister, J R, Rigas, C L, Densmore, G, Krol, R T, Heelan, F M, Sirotnak, J R, Bertino, M G, Kris
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 2(11)
Our objective was to determine the maximum tolerated dose and toxicity of i.v. edatrexate with p.o. leucovorin. Thirty-one adults with advanced solid tumors received edatrexate as a 2-h infusion, once a week for 3 weeks, recycled every 28 days. p.o.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e434c566a8b4fcc05e5c915ad09633da
https://pubmed.ncbi.nlm.nih.gov/9816135
https://pubmed.ncbi.nlm.nih.gov/9816135
Publikováno v:
Cancer. 76(5)
Intravenous antiemetic combinations containing a 5-HT3 receptor antagonist (like metoclopramide, ondansetron, or granisetron) with dexamethasone have become the standard therapy for the treatment of acute chemotherapy-induced vomiting. Intravenous an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::166f5676835b339ee038174bee6d5194
https://pubmed.ncbi.nlm.nih.gov/8625179
https://pubmed.ncbi.nlm.nih.gov/8625179
Publikováno v:
Cancer. 73(3)
Serotonin has been shown to be an important mediator of chemotherapy-induced vomiting. Ondansetron is a potent and highly specific antagonist of the 5-HT3 serotonin receptor. The objective of the current trial was to determine if the addition of onda
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a512eada4c0bdd431784c875012ae56d
https://pubmed.ncbi.nlm.nih.gov/8299095
https://pubmed.ncbi.nlm.nih.gov/8299095
Publikováno v:
Cancer. 72
Combinations of drugs have become standard therapy for the prevention of vomiting caused by anticancer drugs like cisplatin. Recently, a new class of antiemetic agents, the potent and specific 5-HT3 receptor antagonists such as ondansetron, granisetr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed66e933fe44fcfaf7ddf788c6127765
https://pubmed.ncbi.nlm.nih.gov/8242576
https://pubmed.ncbi.nlm.nih.gov/8242576
Publikováno v:
Cancer. 72(9)
RG 12915 is a potent, selective 5-HT3 receptor antagonist with a biologic half-life of 11-20 hours. RG 12915 prevents cisplatin-induced emesis in ferrets at doses of 0.03 mg/kg. Animal toxicology studies permitted safe testing in humans at doses of u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fe9fcfd8ff0f60f6be5124a9545d7c72
https://pubmed.ncbi.nlm.nih.gov/8402492
https://pubmed.ncbi.nlm.nih.gov/8402492
Publikováno v:
Cancer. 71(1)
Tropisetron (ICS 205-930) antagonizes the serotonin type 3 receptor and has antiemetic activity in animals given cisplatin. Its mean serum half-life in 11.1 hours.In this dose-ranging trial, 22 patients undergoing anti-cancer chemotherapy received 24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::632577571b0eb52c5fd264e4bab65b4c
https://pubmed.ncbi.nlm.nih.gov/8416720
https://pubmed.ncbi.nlm.nih.gov/8416720
Publikováno v:
Cancer. 70
Despite excellent control of vomiting during the initial 24 hours after chemotherapy with combination antiemetics, most patients who receive cisplatin at doses of 120 mg/m2 experience delayed emesis 24-120 hours after chemotherapy.Twenty patients rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e316227b071ee41fdb6c392becfbbc6d
https://pubmed.ncbi.nlm.nih.gov/1386282
https://pubmed.ncbi.nlm.nih.gov/1386282
Publikováno v:
European journal of cancer (Oxford, England : 1990). 27
Major progress in the ability to control chemotherapy-induced emesis has been made over the past 10 years. One of the several factors contributing to this improved control has been the development of accurate assessment methodology. The application o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::755344029a5605cb28fae2f46f7a4447
https://pubmed.ncbi.nlm.nih.gov/1831632
https://pubmed.ncbi.nlm.nih.gov/1831632
Autor:
L. B. Tyson
Publikováno v:
Quarterly Journal of Speech. 19:219-224
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d61fc2963ede3b902ddf5589655dbbb
https://doi.org/10.1080/00335633309379944
https://doi.org/10.1080/00335633309379944